[1]Torre Lindsey A,Bray Freddie,Siegel Rebecca L,et al.Global Cancer Statistics,2012［J］.CA:A Cancer Journal for Clinicians,2015,65(2):87-108.
[2]Chen WQ,Zheng RS,Zhang SW,et al.Analysis of morbidity and mortality of malignant tumor in China in 2012［J］.China Cancer,2016,25(1):1-8.［陈万青,郑荣寿,张思维,等.2012年中国恶性肿瘤发病和死亡分析［J］.中国肿瘤,2016,25(1):1-8.］
[3]Zhang Xiaoyuan,Huang Peng,Li Yanjing,et al.The research progress of advanced primary liver cancer treatment［J］.Modern Oncology,2017,25(10):1655-1659.［张晓媛,黄鹏,李燕京,等.晚期原发性肝癌治疗的研究进展［J］.现代肿瘤医学,2017,25(10):1655-1659.］
[4]Liang SX,Zhu XD,Xu ZY,et al.Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma:The risk factors and hepatic radiation tolerance［J］.Int J Radiat Oncol Biol Phys,2006,65(2):426-434.
[5]Ursino S,Greco C,Cartei F,et al.Radiotherapy and hepatocellular carcinoma:Update and review of the literature［J］.European Review for Medical and Pharmacological Sciences,2012,16:1599-1604.
[6]Mornex F,Girard N,Beziat C,et al.Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies-mature results of the French Phase Ⅱ RTF-1 trial［J］.Int J Radiat Oncol Biol Phys,2006,66:1152-1158.
[7]Girard N,Mornex F.External radiotherapy for hepatocellular carcinoma［J］.Cancer Radiother,2006,15:49-53.
[8]Wang C,Li S,Sun A,et al.The comparison of outcomes between hypofractionated and conventional 3D-CRT regimens used in combination with TACE as first-line treatment of advanced hepatocellular carcinoma［J］.Tumour Biol,2015,36(7):4967-4972.
[9]Wang JY,Ding GS.The research progress of treatment of arsenic trioxide for liver cancer［J］.Chinese Journal of General Surgery,2014，23（1）：102-105.［王纪渊，丁国善.三氧化二砷治疗肝癌的研究进展［J］.中国普通外科杂志，2014，23（1）：102-105.］
[10]Peng GZ,Ye QF,Wang L.The method of Arsenic trioxide and combination for the treatment of liver cancer［J］.Journal of Hepatopancreatobiliary Surgery,2016,28(6):441-447.［彭贵主,叶啟发,王垒.三氧化二砷治疗肝癌的出路—联合用药［J］.肝胆胰外科杂志,2016,28(6):441-447.］
[11]Zhang TD,Li YS. The clinical research of treatment of arsenous acid injection for acute myeloid leukemia［J］.Chinese Journal of Integrated Traditional and Western Medicine, 1984, 4(01):19-20.［张亭栋,李元善. 癌灵Ⅰ号治疗急性粒细胞白血病临床分析及实验研究［J］.中国中西医结合杂志,1984,4(01):19-20.］
[12]Hu Qin,Wei Yongming,Guan Rui,et al.Clinical effect of transcatheter arterial chemoembolization combined with arsenic trioxide in the treatment of primary liver cancer［J］.Modern Oncology,2014,22(11):2679-2681.［胡琴,韦永明,管睿,等.TACE联合三氧化二砷治疗原发性肝癌的临床研究［J］.现代肿瘤医学，2014,22(11):2679-2681.］
[13]Qu FL,Hao XZ,Qin SK,et al.The Ⅱ multi-center clinical research of treatment of arsenous acid injection for primary liver cancer［J］.Chinese Journal of Oncology,2011,33（9）：697-701.［屈凤莲，郝学志，秦叔逵，等．亚砷酸注射液治疗原发性肝癌的Ⅱ期多中心临床研究［J］．中华肿瘤杂志，2011,33（9）：697-701.］
[14]Hu SF.The application and observe clinical effect of arsenic trioxide in interventional chemotherapy of liver cancer［J］.China Practical Medicine,2016,11(14):160-161.［胡世峰.三氧化二砷在肝癌介入化疗中的应用及临床效果观察［J］.中国实用医药,2016,11(14):160-161.］